Compounds having S1P5 receptor agonistic activity
AssigneeOno Pharmaceutical Co., Ltd.
InventorsToshihide Watanabe, Kensuke Kusumi, Satomi Imaide, Toshimitsu Endo, Takaki Komiya, Naomi Tsuburaya
Life of this patent
Estimating the term…
Abstract
A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
Claims9
A method for treating an S1P5-mediated disease in a subject in need thereof, comprising administering an effective amount of 1-[[(3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof to the subject.
A method for treating an S1P5-mediated disease in a subject in need thereof, comprising administering an effective amount of a compound of the following structure:
- to the subject.
A method for treating an S1P5-mediated disease in a subject in need thereof, comprising administering an effective amount of a pharmaceutically acceptable salt of the compound of the following structure:
- to the subject.
Dependencies are inferred from the claim text.